44.50
price up icon1.57%   0.69
after-market アフターアワーズ: 44.64 0.14 +0.31%
loading
前日終値:
$43.81
開ける:
$44.245
24時間の取引高:
6.15M
Relative Volume:
1.69
時価総額:
$7.40B
収益:
$1.06B
当期純損益:
$-326.58M
株価収益率:
-21.17
EPS:
-2.1022
ネットキャッシュフロー:
$-977.73M
1週間 パフォーマンス:
+0.14%
1か月 パフォーマンス:
-30.00%
6か月 パフォーマンス:
-38.79%
1年 パフォーマンス:
-29.33%
1日の値動き範囲:
Value
$43.62
$45.28
1週間の範囲:
Value
$43.01
$46.41
52週間の値動き範囲:
Value
$43.01
$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1067)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
1,402
Name
Twitter
@ionispharma
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IONS icon
IONS
Ionis Pharmaceuticals Inc
44.50 7.40B 1.06B -326.58M -977.73M -2.1022
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-21 開始されました Canaccord Genuity Buy
2026-04-10 再開されました Raymond James Outperform
2026-01-28 再開されました Barclays Overweight
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Sep 24, 2026

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide - finance.yahoo.com

Sep 24, 2026
pulisher
Sep 24, 2026

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits

Sep 24, 2026
pulisher
Sep 24, 2026

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis - finance.yahoo.com

Sep 24, 2026
pulisher
Sep 24, 2026

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada

Sep 24, 2026
pulisher
Sep 24, 2026

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data - Investing.com

Sep 24, 2026
pulisher
Sep 24, 2026

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS) - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Oppenheimer reiterates Ionis stock rating on late-stage wins By Investing.com - Investing.com Canada

Sep 24, 2026
pulisher
Sep 23, 2026

Ionis Pharmaceuticals, Inc. (IONS) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Otsuka, Ionis notch phase III win in FUS-ALS - BioWorld News

Sep 23, 2026
pulisher
Sep 23, 2026

IONIS Pharmaceuticals (NASDAQ: IONS) Announces Positive Interim Phase 3 Data for Sefaxersen in IgA Nephropathy - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis Pharmaceuticals and Roche Announce Positive Phase 3 Interim Results for Sefaxersen in IgA Nephropathy - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research

Sep 23, 2026
pulisher
Sep 23, 2026

Roche, Ionis RNA drug scores in kidney disease study - BioPharma Dive

Sep 23, 2026
pulisher
Sep 23, 2026

IONS Looks 5.2% Undervalued on GF Value™ Amid RNA Therapy Trial News - gurufocus.com

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint - Mugglehead Investment Magazine

Sep 23, 2026
pulisher
Sep 23, 2026

Otsuka, Ionis to Discuss Approval Path for FUS-ALS Drug With Regulators - GenomeWeb

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis Pharmaceuticals stock hits 52-week low at $44.20 By Investing.com - Investing.com India

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis Pharmaceuticals stock hits 52-week low at $44.20 - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data By Investing.com - Investing.com Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Roche, Ionis post trial win for kidney drug (IONS:NASDAQ) - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease - Benzinga

Sep 23, 2026
pulisher
Sep 23, 2026

Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.com - Investing.com Nigeria

Sep 23, 2026
pulisher
Sep 23, 2026

Canaccord reiterates Ionis stock rating on positive trial results By Investing.com - Investing.com Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen - Yahoo

Sep 23, 2026
pulisher
Sep 23, 2026

Otsuka and Ionis report positive Phase III readout for ulefnersen - The Pharma Letter

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - BioSpace

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis, Roche report positive phase 3 data for kidney drug - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Ionis, Roche report positive phase 3 data for kidney drug By Investing.com - Investing.com Australia

Sep 23, 2026
pulisher
Sep 22, 2026

Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 22, 2026
pulisher
Sep 22, 2026

IONS Looks 7.0% Undervalued on GF Value™ - gurufocus.com

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis to Seek Expedited FDA Review for ALS Drug - Benzinga

Sep 22, 2026
pulisher
Sep 22, 2026

IONS Looks 7.2% Undervalued on GF Value™ Amid Mixed Growth and P - gurufocus.com

Sep 22, 2026
pulisher
Sep 22, 2026

Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView

Sep 22, 2026
pulisher
Sep 22, 2026

Otsuka, Ionis’ experimental ALS drug meets main goal in late-stage study - 101 WIXX

Sep 22, 2026
pulisher
Sep 22, 2026

JPMorgan cuts Ionis Pharmaceuticals stock price target on launch concerns By Investing.com - Investing.com UK

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis drug meets primary goal in rare ALS gene mutation trial - Investing.com Canada

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis drug meets primary goal in rare ALS gene mutation trial By Investing.com - Investing.com South Africa

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile - TradingView

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis Pharmaceuticals Price Target Cut to $70.00/Share From $76.00 by JP Morgan - Moomoo

Sep 22, 2026
pulisher
Sep 22, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - finance.yahoo.com

Sep 22, 2026
pulisher
Sep 21, 2026

(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Sep 21, 2026
pulisher
Sep 21, 2026

High Growth Tech Stocks To Watch In The US September 2026 - simplywall.st

Sep 21, 2026
pulisher
Sep 21, 2026

Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook On An 88.61% Potential Upside - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 20, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - finance.yahoo.com

Sep 20, 2026
pulisher
Sep 20, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool

Sep 20, 2026
pulisher
Sep 19, 2026

Ionis Pharmaceuticals Stock Plummets Yet Analysts Remain Optimistic - Intellectia AI

Sep 19, 2026
pulisher
Sep 19, 2026

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks - finance.yahoo.com

Sep 19, 2026
pulisher
Sep 18, 2026

Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention? - Yahoo Finance

Sep 18, 2026
pulisher
Sep 18, 2026

IONS Looks 6.5% Undervalued on GF Value™ Despite Challenging Fun - GuruFocus

Sep 18, 2026

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):